Researchers mapped unique glycan, or sugar molecule, patterns on the outer surface of cancer cells that could serve as biomarkers for very early non-invasive cancer screening. The work focuses on how altered sugar coatings distinguish malignant cells from healthy tissue in laboratory assays.
Diagnostic developers are exploring blood tests and imaging probes that detect these glycan signatures before tumours grow large enough for conventional scans to capture. Oncologists said early detection could shift treatment toward less aggressive interventions when disease burden remains small.
Validation requires large patient cohorts across cancer types because glycan profiles may vary by organ and mutation background. Regulatory pathways for screening tests demand rigorous false-positive control to avoid unnecessary biopsies.
Academic teams published structural maps intended to accelerate partner licensing for clinical prototype kits. Funding agencies view glycobiology as an underexplored frontier relative to DNA-based liquid biopsies already entering practice.
Commercial rollout timelines remain uncertain pending multi-center trials confirming sensitivity and specificity in real-world screening populations.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/health/